Jason A. Konner, MD, medical oncologist, Memorial Sloan Kettering Cancer, discusses preferred platinum doublet chemotherapies in the treatment of patients with recurrent ovarian cancer.
Jason A. Konner, MD
Advertisement
Articles by Jason A. Konner, MD
Jason A. Konner, MD, Gynecologic Medical Oncology Service, Memorial Sloan-Kettering Cancer Center, discusses the uncertain path of PARP inhibitors for the treatment of ovarian cancer.
Jason A. Konner, MD, from Memorial Sloan-Kettering Cancer Center, explains that one of the main drivers behind research into bevacizumab in ovarian cancer is to identify which patients will benefit the most from the treatment.
Advertisement
Latest Updated Articles
Dr. Konner on Preferred Platinum Doublets in Recurrent Ovarian CancerPublished: May 18th 2019 | Updated:
Dr. Konner on Bevacizumab in Ovarian CancerPublished: November 16th 2012 | Updated:
Dr. Konner Discusses PARP Inhibitors in Ovarian CancerPublished: February 4th 2013 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Approval Tees Up T-DXd Plus Pertuzumab as a New SOC in HER2+ Breast Cancer
2
Iberdomide Plus Daratumumab/Dexamethasone Displays High Response Rates in NDMM
3
FDA Advises on Next Steps for Nogapendekin Alfa Inbakicept Plus BCG sBLA in BCG-Unresponsive Papillary NMIBC
4
NALIRIFOX and FOLFIRINOX Facilitate Personalized Treatment in Metastatic Pancreatic Cancer
5